Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population

β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day c...

Descripción completa

Detalles Bibliográficos
Autores: Tamma , Pranita, Villegas, María Virginia
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:Colombia
Institución:Universidad El Bosque
Repositorio:Repositorio U. El Bosque
Idioma:inglés
OAI Identifier:oai:repositorio.unbosque.edu.co:20.500.12495/3503
Acceso en línea:http://hdl.handle.net/20.500.12495/3503
https://doi.org/10.1128/AAC.01094-17
https://repositorio.unbosque.edu.co
Access Level:acceso abierto
Palabra clave:Beta-Lactamas
Inhibidores de beta-Lactamasas
Carbapenémicos
ESBLs
Bloodstream infection
Neutropenia
id CO_d83158aabb4e2e6433abbfcd48468cce
oai_identifier_str oai:repositorio.unbosque.edu.co:20.500.12495/3503
network_acronym_str CO
network_name_str Colombia
repository_id_str
spelling Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient populationUse of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient populationTamma , PranitaVillegas, María VirginiaBeta-LactamasInhibidores de beta-LactamasasCarbapenémicosESBLsBloodstream infectionNeutropeniaβ-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.American Society for MicrobiologyAntimicrobial agents and chemotherapyVillegas, María Virginia [0000-0003-1898-9067]2020-07-15T20:51:25Z2020-07-15T20:51:25Z2017Artículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfapplication/pdf1098-6596http://hdl.handle.net/20.500.12495/3503https://doi.org/10.1128/AAC.01094-17instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquehttps://repositorio.unbosque.edu.coengAntimicrobial agents and chemotherapy, 1098-6596, Vol. 61, Nro. 8, 2017https://aac.asm.org/content/61/8/e01094-17Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessAcceso abierto2017-06-05reponame:Repositorio U. El Bosqueinstname:Universidad El Bosqueinstacron:Universidad El Bosque2022-05-03T02:34:17Z
dc.title.none.fl_str_mv Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population
Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population
title Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population
spellingShingle Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population
Tamma , Pranita
Beta-Lactamas
Inhibidores de beta-Lactamasas
Carbapenémicos
ESBLs
Bloodstream infection
Neutropenia
title_short Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population
title_full Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population
title_fullStr Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population
title_full_unstemmed Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population
title_sort Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population
dc.creator.none.fl_str_mv Tamma , Pranita
Villegas, María Virginia
author Tamma , Pranita
author_facet Tamma , Pranita
Villegas, María Virginia
author_role author
author2 Villegas, María Virginia
author2_role author
dc.contributor.none.fl_str_mv Villegas, María Virginia [0000-0003-1898-9067]
dc.subject.none.fl_str_mv Beta-Lactamas
Inhibidores de beta-Lactamasas
Carbapenémicos
ESBLs
Bloodstream infection
Neutropenia
topic Beta-Lactamas
Inhibidores de beta-Lactamasas
Carbapenémicos
ESBLs
Bloodstream infection
Neutropenia
description β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.
publishDate 2017
dc.date.none.fl_str_mv 2017
2020-07-15T20:51:25Z
2020-07-15T20:51:25Z
dc.type.none.fl_str_mv Artículo de revista
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 1098-6596
http://hdl.handle.net/20.500.12495/3503
https://doi.org/10.1128/AAC.01094-17
instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
https://repositorio.unbosque.edu.co
identifier_str_mv 1098-6596
instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
url http://hdl.handle.net/20.500.12495/3503
https://doi.org/10.1128/AAC.01094-17
https://repositorio.unbosque.edu.co
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Antimicrobial agents and chemotherapy, 1098-6596, Vol. 61, Nro. 8, 2017
https://aac.asm.org/content/61/8/e01094-17
dc.rights.none.fl_str_mv Acceso abierto
http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
Acceso abierto
2017-06-05
rights_invalid_str_mv Acceso abierto
http://purl.org/coar/access_right/c_abf2
2017-06-05
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Society for Microbiology
Antimicrobial agents and chemotherapy
publisher.none.fl_str_mv American Society for Microbiology
Antimicrobial agents and chemotherapy
dc.source.none.fl_str_mv reponame:Repositorio U. El Bosque
instname:Universidad El Bosque
instacron:Universidad El Bosque
instname_str Universidad El Bosque
instacron_str Universidad El Bosque
institution Universidad El Bosque
reponame_str Repositorio U. El Bosque
collection Repositorio U. El Bosque
_version_ 1825051199713312768
score 15,812429

Similares en LA Referencia